<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471210</url>
  </required_header>
  <id_info>
    <org_study_id>CA186-011</org_study_id>
    <secondary_id>2012-000170-28</secondary_id>
    <nct_id>NCT01471210</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability, pharmacokinetics and&#xD;
      immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or&#xD;
      metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Every 3 weeks from Baseline (Day 1) for up to 2 years</time_frame>
    <description>The incidence of adverse events will be tabulated and reviewed for potential significance and clinical Importance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities</measure>
    <time_frame>Every 3 weeks from Baseline (Day 1) for up to 9 weeks of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentrations (Cmax) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed serum concentrations (Cmin) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 2 Day 1, Cycle 3 Day 1, every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513)</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Anti-human Antibodies</measure>
    <time_frame>Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years</time_frame>
    <description>Immunogenicity of Urelumab (BMS-663513), as determined by blood sample measurements of human antihuman antibodies (HAHA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response</measure>
    <time_frame>9 weeks from Baseline (Day 1) and every 9 weeks until disease progression, death or last tumor assessment (Approximately up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1 : Urelumab (BMS-663513) Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urelumab (BMS-663513) solution administered intravenously on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 : Urelumab (BMS-663513) Cohort Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urelumab (BMS-663513) solution administered intravenously on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urelumab (BMS-663513)</intervention_name>
    <arm_group_label>Part 1 : Urelumab (BMS-663513) Dose escalation</arm_group_label>
    <arm_group_label>Part 2 : Urelumab (BMS-663513) Cohort Expansion</arm_group_label>
    <arm_group_label>Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions</arm_group_label>
    <arm_group_label>Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Written Informed Consent&#xD;
&#xD;
               -  The signed informed consent form&#xD;
&#xD;
          2. Target Population&#xD;
&#xD;
               -  Subjects with advanced and/or metastatic solid tumors or B-NHL who are either&#xD;
                  refractory to or have relapsed from standard therapies, or for whom a standard&#xD;
                  therapy does not exist with measurable disease per Response Evaluation Criteria&#xD;
                  in Solid Tumors (RECIST) 1.1 criteria&#xD;
&#xD;
               -  Life expectancy of 12 weeks or greater&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
               -  Adequate organ and marrow function&#xD;
&#xD;
               -  For certain subjects, willing and able to provide pre- and post-treatment fresh&#xD;
                  tumor biopsies&#xD;
&#xD;
          3. Age and Reproductive Status&#xD;
&#xD;
               -  Women of childbearing potential (WOCBP) and men must be using an acceptable&#xD;
                  method of contraception to avoid pregnancy throughout the study and for at least&#xD;
                  4 weeks prior to initiation of dosing, and for at least 60 days after the last&#xD;
                  dose of investigational product in such a manner that the risk of pregnancy is&#xD;
                  minimized&#xD;
&#xD;
               -  WOCBP must have a negative serum or urine pregnancy test [minimum sensitivity 25&#xD;
                  UI/L or equivalent units of human chorionic gonadotrophin (HCG)] within 24 hours&#xD;
                  prior to the start of investigational product&#xD;
&#xD;
               -  Women must not be breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target Disease Exceptions&#xD;
&#xD;
               -  Subjects with known or suspected brain metastasis unless previously treated and&#xD;
                  without evidence of progression&#xD;
&#xD;
               -  Subjects with a history of prior malignancy active within the previous 2 years&#xD;
                  except for locally curable cancers that have been apparently cured&#xD;
&#xD;
               -  Subjects with hepatocellular carcinoma&#xD;
&#xD;
          2. Medical History and Concurrent Diseases&#xD;
&#xD;
               -  Any active autoimmune disease or documented history of autoimmune disease, or&#xD;
                  history of syndrome that required systemic steroids or immunosuppressive&#xD;
                  medications, except for subjects with vitiligo, psoriasis inactive within past 2&#xD;
                  years, resolved childhood asthma/atopy, or thyroid disease controlled by&#xD;
                  replacement therapy without the need for immunosuppression&#xD;
&#xD;
               -  Known or suspected human immunodeficiency virus (HIV) or hepatitis A(acute), B or&#xD;
                  C infection&#xD;
&#xD;
               -  History of any hepatitis (e.g., alcohol or non-alcohol steatohepatitis (NASH),&#xD;
                  drug-related, auto-immune)&#xD;
&#xD;
               -  Evidence of active infection, requiring parenteral anti-bacterial, anti-viral or&#xD;
                  anti-fungal therapy &lt; 7 days prior to administration of study medication&#xD;
&#xD;
               -  History of clinically significant cardiac disease, including but not limited to a&#xD;
                  history (personal or family) of congenital long QT syndrome&#xD;
&#xD;
               -  Grade &gt; 1 QTc prolongation at baseline (&gt; 450 msec by Bazett formula) confirmed&#xD;
                  by a repeat electrocardiogram (ECG)&#xD;
&#xD;
               -  History of myocardial infarction or uncontrolled angina within 12 months prior to&#xD;
                  administration of study drug&#xD;
&#xD;
          3. Physical and Laboratory Test Findings&#xD;
&#xD;
               -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy&#xD;
                  for the entire study period and for up to 12 weeks after the last dose of&#xD;
                  investigational product&#xD;
&#xD;
               -  Women who are pregnant or breastfeeding&#xD;
&#xD;
               -  Women with a positive pregnancy test on enrollment or prior to investigational&#xD;
                  product administration&#xD;
&#xD;
               -  Sexually active fertile men not using effective birth control if their partners&#xD;
                  are WOCBP&#xD;
&#xD;
               -  Positive blood screen for hepatitis A IgM, hepatitis C antibody, hepatitis B&#xD;
                  surface antigen, or HIV-1, -2 antibody&#xD;
&#xD;
          4. Allergies and Adverse Drug Reaction&#xD;
&#xD;
               -  History of allergy to Urelumab (BMS-663513) or related compounds&#xD;
&#xD;
               -  History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a&#xD;
                  prior biologic therapy&#xD;
&#xD;
          5. Prohibited Treatments and/or Therapies&#xD;
&#xD;
               -  The systemic use of the following therapies are prohibited within 28 days of&#xD;
                  first dose of study medication, or longer where indicated:&#xD;
&#xD;
                    1. Use of anti-cancer treatment (including investigational drugs) within 28&#xD;
                       days&#xD;
&#xD;
                    2. Immunosuppressive medications or immunosuppressive doses of systemic&#xD;
                       corticosteroids&#xD;
&#xD;
                    3. Surgery (except minor surgeries,e.g., biopsies) or radiotherapy&#xD;
&#xD;
                    4. Any non-oncology live viral vaccine therapies used for the prevention of&#xD;
                       infectious diseases.&#xD;
&#xD;
               -  Prior treatment with anti-programmed death 1 (anti-PD-1)/Programmed cell death 1&#xD;
                  ligand 1 (PD-L1) or anti-CD137&#xD;
&#xD;
               -  Any subject with the following reported drug-related adverse events on anti-&#xD;
                  Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) will not be permitted on study:&#xD;
                  hepatic, diarrhea/colitis or endocrine adverse events (AE)s Grade ≥ 2, any other&#xD;
                  non-laboratory immune-related AE ≥ Grade 3. Subjects must have minimum 9 week&#xD;
                  washout period between the last dose of anti-CTLA4 and the first dose Urelumab&#xD;
                  (BMS-663513)&#xD;
&#xD;
               -  Prior organ allograft or allogeneic bone marrow transplantation&#xD;
&#xD;
          6. Other Exclusion Criteria&#xD;
&#xD;
               -  Prisoners or subjects who are involuntarily incarcerated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division Of Hematology &amp; Oncology Ctr. For Health Sciences</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Med Ctr</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Of The University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rouen</city>
        <zip>F-76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31192</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2011</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

